Acura Pharmaceuticals, Inc.
ACUR
$0.0002
$0.000.00%
| 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | |
|---|---|---|---|---|---|
| Revenue | 270.00K | 613.00K | 644.00K | 718.00K | 410.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 270.00K | 613.00K | 644.00K | 718.00K | 410.00K |
| Cost of Revenue | 385.00K | 390.00K | 405.00K | 430.00K | 519.00K |
| Gross Profit | -115.00K | 223.00K | 239.00K | 288.00K | -109.00K |
| SG&A Expenses | 416.00K | 523.00K | 385.00K | 419.00K | 456.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 801.00K | 913.00K | 790.00K | 849.00K | 975.00K |
| Operating Income | -531.00K | -300.00K | -146.00K | -131.00K | -565.00K |
| Income Before Tax | -262.00K | -387.00K | -259.00K | -243.00K | -678.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -262.00K | -387.00K | -259.00K | -243.00K | -678.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -262.00K | -387.00K | -259.00K | -243.00K | -678.00K |
| EBIT | -531.00K | -300.00K | -146.00K | -131.00K | -565.00K |
| EBITDA | -512.00K | -282.00K | -128.00K | -112.00K | -545.00K |
| EPS Basic | 0.00 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | 0.00 | -0.01 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 75.56M | 42.89M | 32.46M | 32.37M | 32.34M |
| Average Diluted Shares Outstanding | 75.56M | 42.89M | 32.46M | 32.37M | 32.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
